Log in

NASDAQ:HJLIHancock Jaffe Laboratories Stock Price, Forecast & News

$0.33
-0.01 (-2.98 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.32
Now: $0.33
$0.36
50-Day Range
$0.28
MA: $0.37
$0.47
52-Week Range
$0.21
Now: $0.33
$2.10
Volume263,386 shs
Average Volume476,754 shs
Market Capitalization$6.24 million
P/E RatioN/A
Dividend YieldN/A
Beta1.87
Hancock Jaffe Laboratories, Inc., a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease. Its products include the Bioprosthetic Heart Valve, a bio-prosthetic heart valve designed to mimic and function like a native heart valve; the CoreoGraft, a device for use as an alternate or supplemental coronary vascular conduit in coronary bypass surgery; and the Venous Valve, a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency. The company was founded in 1987 and is headquartered in Irvine, California. As of July 18, 2006, Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HJLI
CUSIPN/A
Phone949-261-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30,000.00
Book Value$0.06 per share

Profitability

Net Income$-7,630,000.00

Miscellaneous

EmployeesN/A
Market Cap$6.24 million
Next Earnings Date6/4/2020 (Estimated)
OptionableNot Optionable

Receive HJLI News and Ratings via Email

Sign-up to receive the latest news and ratings for HJLI and its competitors with MarketBeat's FREE daily newsletter.

Hancock Jaffe Laboratories (NASDAQ:HJLI) Frequently Asked Questions

How has Hancock Jaffe Laboratories' stock been impacted by COVID-19 (Coronavirus)?

Hancock Jaffe Laboratories' stock was trading at $0.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HJLI shares have decreased by 34.8% and is now trading at $0.3260. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Hancock Jaffe Laboratories?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hancock Jaffe Laboratories in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Hancock Jaffe Laboratories.

When is Hancock Jaffe Laboratories' next earnings date?

Hancock Jaffe Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, June 4th 2020. View our earnings forecast for Hancock Jaffe Laboratories.

How were Hancock Jaffe Laboratories' earnings last quarter?

Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) posted its quarterly earnings data on Thursday, October, 31st. The company reported ($0.10) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.14) by $0.04. View Hancock Jaffe Laboratories' earnings history.

What price target have analysts set for HJLI?

1 brokerages have issued 1 year price objectives for Hancock Jaffe Laboratories' shares. Their forecasts range from $3.00 to $3.00. On average, they expect Hancock Jaffe Laboratories' stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 820.2% from the stock's current price. View analysts' price targets for Hancock Jaffe Laboratories.

What are Wall Street analysts saying about Hancock Jaffe Laboratories stock?

Here are some recent quotes from research analysts about Hancock Jaffe Laboratories stock:
  • 1. Maxim Group analysts commented, "Hancock Jaffe announced positive 90-day results from its animal feasibility for CoreoGraft, its off-the-shelf conduit for Coronary Artery Bypass Grafting (CABG)." (8/15/2019)
  • 2. According to Zacks Investment Research, "Hancock Jaffe Laboratories, Inc. is involved in developing and manufacturing bioprosthetic medical devices to treat cardiac and vascular diseases. Its product candidates consists of the porcine tissue based VenoValve, which is intended to be surgically implanted in the deep venous system of the leg to treat Chronic Venue Insufficiency; CoreoGraftÒ, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery and a porcine tissue based heart valve, is an ideal candidate for pediatric aortic/mitral valve replacement. Hancock Jaffe Laboratories, Inc. is based in IRVINE, United States. " (6/26/2019)

Has Hancock Jaffe Laboratories been receiving favorable news coverage?

Media stories about HJLI stock have trended somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Hancock Jaffe Laboratories earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutHancock Jaffe Laboratories.

Who are some of Hancock Jaffe Laboratories' key competitors?

What other stocks do shareholders of Hancock Jaffe Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hancock Jaffe Laboratories investors own include Amarin (AMRN), VBI Vaccines (VBIV), Vaxart (VXRT), Agile Therapeutics (AGRX), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Fortress Biotech (FBIO), Protalix Biotherapeutics (PLX), vTv Therapeutics (VTVT) and Acasti Pharma (ACST).

Who are Hancock Jaffe Laboratories' key executives?

Hancock Jaffe Laboratories' management team includes the following people:
  • Mr. Robert A. Berman, CEO & Director (Age 56)
  • Mr. Robert Rankin, CFO, Sec. & Treasurer (Age 66)
  • Dr. Benedict Broennimann M.D., Chief Medical Officer of Outside of United States (Age 62)
  • Dr. Marc H. Glickman, Sr. VP & Chief Medical Officer (Age 70)
  • Mr. Warren Hancock, Co-founder

When did Hancock Jaffe Laboratories IPO?

(HJLI) raised $8 million in an initial public offering (IPO) on Thursday, May 31st 2018. The company issued 1,500,000 shares at $5.00 per share. Network 1 Financial Securities served as the underwriter for the IPO and ViewTrade Securities was co-manager.

What is Hancock Jaffe Laboratories' stock symbol?

Hancock Jaffe Laboratories trades on the NASDAQ under the ticker symbol "HJLI."

How do I buy shares of Hancock Jaffe Laboratories?

Shares of HJLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Hancock Jaffe Laboratories' stock price today?

One share of HJLI stock can currently be purchased for approximately $0.33.

How big of a company is Hancock Jaffe Laboratories?

Hancock Jaffe Laboratories has a market capitalization of $6.24 million and generates $30,000.00 in revenue each year.

What is Hancock Jaffe Laboratories' official website?

The official website for Hancock Jaffe Laboratories is www.hancockjaffe.com.

How can I contact Hancock Jaffe Laboratories?

Hancock Jaffe Laboratories' mailing address is 70 DOPPLER, IRVINE CA, 92618. The company can be reached via phone at 949-261-2900.

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.